642
Participants
Start Date
June 28, 2023
Primary Completion Date
May 11, 2024
Study Completion Date
May 11, 2024
5% Tavilermide ophthalmic solution
Twice a day topicial dosing
Vehicle ophthalmic solution
Twice a day topical dosing
Rochester Ophthalmological Group, Rochester
Scott & Christie and Associates, Cranberry Township
Seidenberg Protzko Eye Associates, Havre de Grace
Piedmont Eye Center, Lynchburg
James D. Branch, Winston-Salem
Oculus Research, Garner
Eye Consultants of Atlanta, Atlanta
Bowden Eye & Associates, Jacksonville
Shettle Eye Research, Largo
Eye Associates of Fort Myers, Fort Myers
Nature Coast Clinical Research, Crystal River
Toyos Clinic, Nashville
Total Eye Care, Memphis
Abrams Eye Center, Cleveland
Price Vision Group, Indianapolis
Midwest Vision Research Foundation, Chesterfield
Ophthalmology Associates, St Louis
Silverstein Eye Centers, Kansas City
Moyes Eye Center, Kansas City
Kannarr Eye Care, Pittsburg
Advanced Laser Vision & Surgical Institute, Houston
PNV Clinical Research, San Antonio
Lake Travis Eye & Laser Center/Revolution Research, Lakeway
The Eye Institute of Utah, Salt Lake City
Eye Doctors of Arizona, Phoenix
Global Research Management, Glendale
LoBue Laser and Eye Medical Center, Murrieta
Eye Research Foundation, Newport Beach
West Bay Eye Associates, Warwick
Lead Sponsor
Mimetogen Pharmaceuticals USA, Inc.
INDUSTRY